Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHP 303

Next Previous
Search
Drug Profile

PHP 303

Alternative Names: BAY 858501; PHP-303

Latest Information Update: 21 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare
  • Developer Akari Therapeutics; Bayer HealthCare
  • Class Antibronchitics; Benzenesulfonates; Fluorinated hydrocarbons; Hepatoprotectants; Nitriles; Pyrimidines; Small molecules
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alpha 1-antitrypsin deficiency
  • Preclinical Adult respiratory distress syndrome
  • No development reported Non-alcoholic steatohepatitis
  • Discontinued Bronchiectasis

Most Recent Events

  • 14 Nov 2024 Peak Bio has merged with Akari Therapeutics to form Akari Therapeutics
  • 25 Jul 2024 Discontinued - Phase-II for Bronchiectasis (Non-cystic fibrosis-related) in France (PO)
  • 25 Jul 2024 Discontinued - Phase-II for Bronchiectasis (Non-cystic fibrosis-related) in Germany (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top